Among lymphoma survivors experiencing chronic fatigue, a multidisciplinary intervention program has been found to have a ...
MHRA response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025SAN DIEGO, Nov. 02, 2025 (GLOBE ...
LittleTechGirl on MSN
MK-677 (Ibutamoren) For Research: A Practical, Evidence-Focused Overview
MK-677 (also known as ibutamoren or MK-0677) is an orally active ghrelin receptor (GHSR-1a) agonist that increases pul ...
In the field of genetic epidemiology, Mendelian Randomization (MR) has surfaced as a robust tool for assessing causal relationships between various ...
Adjunctive glucocorticoids may reduce mortality among patients with severe community-acquired pneumonia (CAP) in ...
ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY ( NCT06659445) trial evaluating ...
Xelafaslatide is an investigational first-in-class small molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across a range of retinal ...
ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback